Welcome and Introduction by Chair of BHIVA
Dr Laura Waters
Mortimer Market Centre, London
BHIVA Standards of Care - patient version
Mr Ben Cromarty
Yorkshire Mesmac; UK-CAB; MRC CTU at UCL PPI Group, Northallerton
HIV-2 Guidelines
Dr Iain Reeves
Homerton Hospital, London
Dr Clare van Halsema
North Manchester General Hospital
BHIVA Invited Lecture: Lest we forget
The early days
Dr Edmund Wilkins, Medical Action Myanmar, Manchester
Early community involvement
Mr Simon Collins, HIV i-base, London
Clinico-pathological Case Presentations
Case 1: The diagnostic challenge of a non-healing ulcer
Dr Julia Bilinska, Guy’s & St Thomas’ Hospital, London
Case 2: A one of a kind opportunity
Dr Gavin Connolly, Pennine Acute Hospitals NHS Trust, Manchester
Case 3: A multicentre mystery
Dr Mia Oliveira, King’s College Hospital, London
Oral Research Presentations: Session 1 (1–9)
O1 Antiretroviral treatment uptake and outcomes in heterosexual people living with HIV in the United Kingdom according to ethnic group
Rageshri Dhairyawan, Barts Health NHS Trust
O2 The impact of pregnancy on engagement of care (EIC) of women living with HIV in the UK CHIC Study
Hajra Okhai, Institute for Global Health, University College London
O3 Breastfeeding and women with HIV living in the UK; BHIVA guidelines and real world experience
Judith Russell, L+G NHS Trust
O4 Follow-up status of HIV exposed infants in the UK 2012-2019
Kate Francis, Integrated Screening Outcomes Surveillance Service, UCL Great Ormond Street Institute of Child Health
O5 Does the menopause have an impact on virological outcomes and engagement in care (EIC) in UK CHIC participants?
Hajra Okhai, Institute for Global Health, University College London
O6 Measuring health care HIV knowledge within our NHS Trust
Moses Shongwe, Barts Health NHS Trust
O7 Digital health solutions in HIV: supporting a reduced visit pathway of care for people living with medically stable HIV in a UK centre
Jenny Whetham, Brighton and Sussex University Hospitals NHS Trust
O8 POSITIVE OUTCOMES: properties of a novel brief tool to measure and improve person-centred outcomes in routine HIV care
Richard Harding, King's College London
O9 Increasing access to peer-support for people living with HIV in the UK: An evaluation of ‘Project 100’
Garry Brough, Positively UK
Jonathan Ainsworth Memorial Lecture
Introduction
Dr Christopher Wood, North Middlesex University Hospital NHS Trust, London
Case presentation: It could only get better
Professor Rob Miller, University College Hospital, London
The art and the science of HLH
Dr Jessica Manson, University College Hospital, London
Oral Research Presentations: Session 2 (10–15)
O10 Late diagnosis and a lack of engagement with care and treatment are still causing deaths among HIV patients in London
Sara Croxford, Public Health England
O11 Differential effects of HIV antiretrovirals on human coronary artery endothelial cells
A.A. Khawaja, National Heart and Lung Institute, Imperial College London
O12 Mitochondrial DNA damage and brain ageing in HIV
Brendan Payne, Newcastle University
O13 Discontinuation of tenofovir alafenamide (TAF) containing antiretroviral therapy (ART) due to adverse drug reactions (ADRs): experience of four London HIV units
William Hickey, Chelsea and Westminster Hospital NHS Foundation Trust
O14 Respiratory symptoms and chronic bronchitis in people with HIV and demographically-similar HIV-negative controls: prevalence and risk factors
Caroline Sabin, UCL
O15 Incidence and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the UK
Clare van Halsema, North Manchester General Hospital
UK-CAB Community Session: The Contribution of the HIV Community to HIV Care - how we can help you to help us to live our best life with HIV
Introduction
Jo Josh, Session Chair
A decade as a community rep
Memory Sachikonye, UK Community Advisory Board (UK-CAB)
Community Reps on HIV research and guideline groups: 'the bleak and the bright'
Robert James, University of Sussex
Experiences of working with the HIV community
Professor Caroline Sabin, University College London
BHIVA Lunchtime Workshop 1: The BHIVA International Partnerships Working Group
Introduction
Dr Kat Stegmann, Chelsea & Westminster Hospital NHS Trust, London
Pakistan
Dr Clare van Halsema, North Manchester General Hospital
Exchange reports
Dr Alastair Duncan, Guy's and St Thomas' NHS Foundation Trust, London
Dr Janetta Harbron, University of Cape Town, South Africa
Dr Padmasayee Papineni, London North West University Healthcare NHS Trust
Dr Diarmuid Nugent, Chelsea & Westminster Hospital NHS Trust, London
Summary, acknowledgements, and future plans
Dr Tristan Barber, Royal Free London NHS Foundation Trust
BHIVA Lunchtime Workshop 2: Understanding recent acquisition of HIV in the UK
Surveillance of HIV Acquired Recently: Enhanced (SHARE)
Adamma Aghaizu, Public Health England, London
Recently acquired HIV - clinician and patient perspectives
Dr Iain Reeves, Homerton Hospital, London & Greg Owen, iwantPrEPnow, London
Oral Research Presentations: Session 3 (16–24)
O16 Measuring endemic transmission of HIV in the United Kingdom: implications for HIV elimination
Sara Croxford, Public Health England
O17 ‘Get Tested LeEDs’: Testing for blood borne viruses (BBV) via notional consent in Emergency Departments (ED)
Khine Phyu, Leeds Teaching Hospitals Trust
O18 High level compliance to opt out HIV testing in the Emergency Department (ED) of a large teaching hospital using the biochemistry sample as the sample type for HIV screening
Rebecca Marchant, St George's University Hospital NHS Foundation Trust
O19 BBV_TestPrompt: Using technology to increase blood-borne virus testing in primary care
Christopher Lawrence, James Cook University Hospital
O20 Use of HIV Pre-Exposure Prophylaxis among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) in England: Data from the AURAH2 Study
Nadia Hanum, University College London
O21 Increasing awareness of HIV PrEP in African communities using trained community champions
Nadia Ekong, Leeds Teaching Hospitals NHS Trust
O22 Delivery of oral HIV Pre Exposure Prophylaxis for people who inject drugs and are at risk of sexual exposure to HIV during an outbreak
Ceilidh Grimshaw, Sandyford Initiative
O23 Factors associated with reported STI-Prophylaxis (“Doxy-PrEP"/"Doxy-PEP”) use among HIV-PrEP users in the UK
John Saunders, Public Health England
O24 Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtrictabsine (tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
Iain Reeves, Homerton Hospitals NHS Trust
The Stigma of HIV
The London hospital perspective
Dr Iain Reeves, Homerton Hospital, London
BHIVA Invited Lecture
Community involvement in HIV research
Longret Kwardem, 4M Mentor Mothers Network CIC
Three Decades of Community Based Research in Canada: Lessons Learned to Face COVID-19
Francisco Ibáñez-Carrasco PhD, Learning Innovation Dalla Lana School of Public Health, University of Toronto
Oral Research Presentations: Session 4 (25–30)
O25 Virological and immunological evaluation of individuals with spontaneous persistent viral control without ART
Maryam Khan, Imperial College London
O26 The use of next generation sequencing technology to detect integrase inhibitor resistance in treatment naïve patients with HIV in Wales
Donall Forde, Public Health Wales
O27 Increase in bone mineral density and weight in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG
Amanda Samarawickrama, Sexual Health South West London
O28 Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are well tolerated and efficacious in people living with HIV
Christopher Robinson, Gilead Sciences Ltd
O29 Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results
Chloe Orkin, Queen Mary University
O30 Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study
Paul D Benn, ViiV Healthcare
BHIVA Lunchtime Workshop 3: Neurosyphilis
A clinical perspective
Dr Patrick French, Mortimer Market Centre, London
Epidemiology and control of syphilis
Dr Michael Marks, London School of Hygiene and Tropical Medicine
BHIVA Lunchtime Workshop 4: Hepatitis
Micro elimination as a concept
Dr Jeffrey Lazarus, IS Global, Barcelona
PHE and the plans for elimination
Dr Emily Phipps, Public Health England, London
Regional HCV elimination - the importance of micro elimination in PLWH
Dr Andrew Ustianowski, North Manchester General Hospital
PHE Survey Feedback
What Happened with COVID-19? – BHIVA/CHIVA/PHE Survey Feedback
Dr Gabriella Shanks, Mortimer Market Centre, London
Panel Discussion
Professor Jane Anderson, Homerton Hospital, London
Dr David Asboe, Chelsea & Westminster Hospital, London
Close by Chair of BHIVA
Dr Laura Waters, Mortimer Market Centre, London